权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Using Affymetrix Microflora array to study microflora composition in children wit

使用 Affymetrix Microflora 芯片研究智障儿童的微生物群组成

基本信息

批准号：
7686884
负责人：
OLEG PALIY
金额：
$ 17.94万
依托单位：
WRIGHT STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-30 至 2011-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7686884
关键词：
Adolescent Adult Affect Aftercare Bacteria Child Childhood Clinical Colon Carcinoma Communities Complementary Medicine Complex Custom Data Detection Development Diarrhea Disease Environment Equipment Evaluation Feces Gastrointestinal tract structure Goals Health Human Individual Inflammatory Bowel Diseases Intestinal Diseases Intestines Irritable Bowel Syndrome Knowledge Lead Location Measurement Medical center Medicine Microarray Analysis Microbiological Techniques Patients Placebos Play Population Probiotics Relative (related person)Research Role Sampling School-Age Population Scientist Screening procedure Statistical Data Interpretation Structure Symptoms System Technology Testing Time Treatment outcome Wit Work base design experience innovation knowledge base microbial microorganism novel therapeutics public health relevance

项目摘要

DESCRIPTION (provided by applicant): In the healthy human, there are billions of bacteria colonizing the intestine. This intestinal microflora is a complex community of microorganisms that plays a role in several intestinal diseases such as inflammatory bowel disease, irritable bowel syndrome (IBS), and colon cancer. Among these, IBS is a common disorder in children, affecting up to 25% of school-age children and adolescents. However, our knowledge of the changes in microflora in IBS and other diseases is incomplete. There is a lack of quantitative measurements of microflora differences between healthy and ill individuals. Moreover, while both children and adults suffer from these disorders, the majority of previous studies were carried out in adults. Our lack of understanding of microflora dynamics during intestinal diseases retards the development and evaluation of new and exciting medicines, such as probiotics. Our long-term goal is to study microflora dynamics during intestinal disorders and to assess the use of probiotics as treatment options for such illnesses. In this project, using a custom microarray specifically designed by us to study microflora structure in the human gastrointestinal tract, we will quantitatively compare the microflora composition in the feces of healthy children with that in children with IBS; and we will test if the use of probiotic VSL#3 to treat children suffering from IBS will lead to specific changes in microflora composition to mirror that of healthy children. The potential for screening of microflora in patients suffering from intestinal disorders before the onset of probiotic treatment can provide useful information on microflora status that would help in the choice of an appropriate probiotic therapy. At the same time, the ability to assess changes in microflora during probiotic treatment will provide direct information on the effect of probiotics on the microflora community. PUBLIC HEALTH RELEVANCE: Intestinal microflora is a complex community of microorganisms that is believed to play a role in several intestinal diseases such as irritable bowel syndrome (IBS). Though there is evidence that the gut flora of IBS patients differs from that of the healthy individuals, we still lack the understanding of specific microflora changes in IBS. The paucity of such knowledge leads to difficulties in interpretation of the results of IBS treatments, particularly those involving probiotics. The research proposed in this application will profile microflora composition in healthy children and in children with IBS undergoing probiotic treatment. The comparisons of microflora composition between these children will i) provide information on microflora status during IBS in children and its changes as a result of probiotic treatment, ii) expedite the evaluation and development of new therapeutic options such as probiotic agents aimed to restore normal microflora composition; and iii) establish the base of knowledge on microflora composition necessary for further studies of probiotic effects on microflora.

描述（由申请人提供）：在健康人的肠道中，有数十亿细菌定植。这种肠道菌群是一个复杂的微生物群落，在炎症性肠病、肠易激综合征 (IBS) 和结肠癌等多种肠道疾病中发挥着重要作用。其中，IBS是儿童常见疾病，影响高达25%的学龄儿童和青少年。然而，我们对肠易激综合症和其他疾病中微生物群落变化的了解并不完整。缺乏对健康个体和患病个体之间微生物区系差异的定量测量。此外，虽然儿童和成人都患有这些疾病，但之前的大多数研究都是在成人中进行的。我们对肠道疾病期间微生物群动态缺乏了解，阻碍了益生菌等令人兴奋的新药物的开发和评估。我们的长期目标是研究肠道疾病期间的微生物群动态，并评估益生菌作为此类疾病的治疗选择的用途。在这个项目中，我们将使用我们专门设计的用于研究人类胃肠道微生物结构的定制微阵列，定量比较健康儿童和IBS儿童粪便中的微生物组成；我们将测试使用益生菌 VSL#3 治疗患有 IBS 的儿童是否会导致微生物群组成发生特定变化，以反映健康儿童的微生物群组成。在开始益生菌治疗之前对患有肠道疾病的患者进行微生物群落筛查可以提供有关微生物群落状态的有用信息，从而有助于选择适当的益生菌疗法。同时，评估益生菌治疗期间微生物群落变化的能力将提供益生菌对微生物群落影响的直接信息。公共卫生相关性：肠道菌群是一个复杂的微生物群落，被认为在肠易激综合征 (IBS) 等多种肠道疾病中发挥着作用。尽管有证据表明 IBS 患者的肠道菌群与健康个体不同，但我们仍然缺乏对 IBS 特定微生物群变化的了解。缺乏此类知识导致难以解释 IBS 治疗的结果，特别是涉及益生菌的治疗。本申请中提出的研究将分析健康儿童和接受益生菌治疗的肠易激综合征儿童的微生物群组成。这些儿童之间微生物群组成的比较将 i) 提供有关儿童 IBS 期间微生物群状态及其因益生菌治疗而发生的变化的信息，ii) 加快评估和开发新的治疗方案，例如旨在恢复正常微生物群组成的益生菌制剂； iii) 建立进一步研究益生菌对微生物群落影响所需的微生物群落组成知识基础。